The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Patients With Secondary Poor… (NCT06792682) | Clinical Trial Compass
RecruitingPhase 1
The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Patients With Secondary Poor Graft Function After Hematopoietic Stem Cell Transplantation
China15 participantsStarted 2025-02-14
Plain-language summary
This study is conducted in a prospective, single-center clinical design and is divided into two stages: dose escalation and dose extension. Patients meeting the diagnostic criteria of secondary poor graft function are selected as the study objects. The safety data of umbilical cord blood mononuclear cells in the treatment of secondary poor graft function are obtained through dose escalation stage, and then one dose is selected for dose extension stage to explore the efficacy of umbilical cord blood mononuclear cells in treating secondary poor graft function.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age≥18 years old; gender is not limited.
✓. Meet the diagnostic criteria for secondary poor graft function: After 28 days of transplantation, patients who had achieved hematopoietic reestablishment (ANC ≥ 0.5×10\^9/L for 3 consecutive days without G-CSF application, PLT ≥ 20×10\^9/L for 7 consecutive days without platelet infusion, Hb ≥ 80g/L for 2 consecutive weeks without red blood cell infusion) again developed two or three line cytopenia lasting more than 2 weeks. Bone marrow examination revealed low myelodysplasia, remission of primary disease, complete donor chimeric cells, and no severe graft-versus-host disease (GVHD) or disease recurrence.
✓. Eastern Cooperative Oncology Group (ECOG) physical status score ≤ 2 points.
✓. Subjects sign informed consent.
Exclusion criteria
✕. Serious infection not controlled.
✕. Active bleeding.
✕. Patients with cardiac insufficiency (ejection fraction\<50%), or suffering from serious heart disease, including myocardial infarction, cardiac insufficiency, etc.
What they're measuring
1
Safety assessment
Timeframe: From date of the last infusion of umbilical cord blood mononuclear cells until the date of end of follow-up, assessed up to 24 months
Trial details
NCT IDNCT06792682
SponsorInstitute of Hematology & Blood Diseases Hospital, China
. Patients with hepatic and renal insufficiency (total bilirubin\>35µmol/L, ALT and AST\>2 times of the upper limit of normal; serum creatinine\>130µmol/L).
✕. Pregnant or lactating women.
✕. Concurrent malignant tumors of other organs.
✕. Failure to understand or follow the research protocol.
✕. Patients participating in other clinical investigations.